Press Release
View printer-friendly version << Back
vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
TTP399, a novel glucokinase activator shows statistically significant reduction in HbA1c without increases in ketones or hypoglycemia
In this double-blind, placebo-controlled 12-week trial, the baseline mean HbA1c for the groups treated with TTP399 and placebo was 7.3% and 7.4%, respectively. Patients treated with TTP399 (n=8) showed a statistically significant mean reduction in HbA1c of 0.6% at 12 weeks, while the group treated with placebo (n=11) showed a mean increase in HbA1c of 0.1%, resulting in a mean difference of 0.7% in the TTP399 group relative to the placebo group (p=0.03). At the same time, trends toward decreased insulin usage were observed in the group treated with TTP399.
Patients in this study received insulin adjustments to optimize glucose levels. As a result, the primary analysis included a responder analysis in which a ‘treatment responder’ was defined as a patient who had a decrease in HbA1c at Week 12, no abnormal lactate or ketones detected in blood or urine during the study, and no increased time in Level 2 hypoglycemia (blood glucose <54 mg/dl). Of all study patients, there was a greater proportion of responders in the group treated with TTP399 (75%) than in the placebo group (9%) (p=0.006). Consistent with the treatment responder results, abnormal ketones were observed in plasma or urine in 63% of patients on placebo vs. 13% of patients treated with TTP399.
TTP399 was well tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class. The study had no serious adverse event reported. The study also had no report of diabetic ketoacidosis or severe hypoglycemia.
“These results from a small group of patients with type 1 diabetes are
very exciting. If they hold up in part 2 of the trial, TTP399 will be
the most impressive adjunctive therapy to insulin in type 1 diabetes
care,” said Dr.
More detailed study results will be presented at the 55th
Annual Meeting of the
“While insulin remains the main line of treatment for T1D, we believe
that adjunctive treatments such as TTP399 can lead to improvements in
metabolic balance and favorable treatment outcomes for people living
with T1D,” said Esther Latres, Ph.D., JDRF Director Research. “We are
encouraged by the initial results and look forward to critical
additional evidence to ascertain the benefits of this therapy and laud
the efforts of
“We are excited that TTP399 has demonstrated clinically meaningful
efficacy as an adjunct therapy for T1D in this group of patients, and
are pleased to have seen a favorable safety profile consistent with what
we have seen in our previous trials in patients with type 2 diabetes,”
said
About TTP399
The glucokinase enzyme (GK) is a key regulator
of glucose metabolism, and its activation has been shown to increase
glucose utilization, which in turn lowers blood glucose. TTP399 is an
orally available GK activator that is designed for superior glucose
control by targeting GK activation only in the liver with an
insulin-independent mechanism of action.
TTP399 has been studied in 12 clinical trials to date, including a 6-month Phase 2b trial in patients with type 2 diabetes where it demonstrated sustained, meaningful reductions in HbA1c and was well-tolerated, with negligible incidences of hypoglycemia and hyperlipidemia, and no occurrences of diabetic ketoacidosis.
About Simplici-T1
Simplici-T1 is a multi-center, randomized,
double-blind, adaptive study assessing the pharmacokinetics,
pharmacodynamics, safety and tolerability of TTP399 as an adjunct to
insulin therapy in adult patients with T1D. The study is being conducted
with support from JDRF, the leading global organization funding research
in type 1 diabetes.
The Phase 2 learn and confirm study is being conducted in two parts to
evaluate the safety and efficacy of TTP399 in T1D patients over twelve
weeks of daily dosing. Part 1 enrolled 20 patients on both insulin pumps
and CGM’s. Part 2 is currently enrolling up to approximately 90 patients
using either insulin pumps or multiple daily injection therapy, with
CGMs optional. Enrollment of patients in Part 2 of the study commenced
in
About Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune
disease in which a person’s pancreas stops producing insulin, a hormone
that enables people to get energy from food. It occurs when the body’s
immune system attacks and destroys the insulin-producing cells in the
pancreas, called beta cells. While its causes are not yet entirely
understood, scientists believe that both genetic factors and
environmental triggers are involved. Its onset has nothing to do with
diet or lifestyle. There is nothing you can do to prevent T1D, and—at
present—nothing you can do to cure it.
About
vTv
Forward-Looking Statements
This release contains
forward-looking statements, which involve risks and uncertainties. These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “anticipate,”
“believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” “would”
and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
These forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law, we
undertake no obligation to update or review publicly any forward-looking
statements, whether as a result of new information, future events or
otherwise after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of any
future acquisitions, merger, dispositions, joint ventures or investments
we may undertake. We qualify all of our forward-looking statements by
these cautionary statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005155/en/
Source:
Investors:
vTv Therapeutics Inc.
IR@vtvtherapeutics.com
or
Media:
Josh
Vlasto
212-572-5969
PR@vtvtherapeutics.com